Drugs Made In America Acquisition (DMAA) Fundamentals 2026 — P/E 52.3x, Revenue Analysis | SniperIQ
Drugs Made In America Acquisition (DMAA) is a US-listed Financial Services company in Shell Companies with a market capitalization of
Drugs Made In America Acquisition (DMAA) has a market capitalization of approximately
Drugs Made In America Acquisition's trailing twelve-month P/E ratio is 52.3x, with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Financial Services sector peers rather than read in isolation.
Drugs Made In America Acquisition runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Drugs Made In America Acquisition does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Drugs Made In America Acquisition carries a debt-to-equity ratio of 0.00x and a current ratio of 0.03x, with a market beta of 0.00. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Drugs Made In America Acquisition (DMAA) the key facts are: market cap
Get Drugs Made In America Acquisition's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.